CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM
Junmin Song compared BCMA treatments for multiple myeloma at ESMO Congress 2024, finding CAR T-cell therapies (ide-cel, cilta-cel) improved overall survival over bispecific antibody teclistamab. CAR T-cell therapy showed lower mortality rates and higher risk of cytokine release syndrome. Older, transplant-ineligible patients benefited more from CAR T-cell therapy.
Reference News
CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM
Junmin Song compared BCMA treatments for multiple myeloma at ESMO Congress 2024, finding CAR T-cell therapies (ide-cel, cilta-cel) improved overall survival over bispecific antibody teclistamab. CAR T-cell therapy showed lower mortality rates and higher risk of cytokine release syndrome. Older, transplant-ineligible patients benefited more from CAR T-cell therapy.